GeoVax Labs, Inc. Warrants - GOVXW STOCK NEWS

The press release dated April 18, 2022, from GeoVax, Inc. was mistakenly attributed and should have been sourced to Aura FAT Projects Acquisition Corp. This correction clarifies the proper source of the information, ensuring accurate representation in the market. No financial data or significant business developments were provided in the release, indicating that this is a mere administrative update rather than a statement affecting stock performance.

Aura FAT Projects Acquisition Corp. completed its initial public offering (IPO) on April 13, 2022, raising $115 million by issuing 10 million units at $10 each, with an over-allotment of 1.5 million units. Each unit comprises one Class A ordinary share and one redeemable warrant priced at $11.50. The securities are listed on Nasdaq under the ticker symbols AFARU, AFAR, and AFARW. The company seeks to focus on emerging technology sectors in Southeast Asia and Australasia, particularly Web 3.0, blockchain, and digital financial services.

GeoVax Labs (Nasdaq: GOVX) reports significant advancements in its COVID-19 vaccine candidates. The lead candidate, GEO-CM04S1, is undergoing Phase 2 clinical trials for various patient groups. Meanwhile, the experimental GEO-CM02 vaccine showed 100% single-dose protection in animal trials, aiming for universal coronavirus immunity.

Both vaccines utilize the GV-MVA-VLP™ platform, designed to evoke broader immune responses, potentially countering emerging variants like Omicron. Upcoming expert discussions at the World Vaccine Congress highlight the continuing innovation in GeoVax’s vaccine development strategy.

GeoVax Labs (Nasdaq: GOVX) announced the issuance of Patent No. 11278607 for its immunotherapy candidate targeting the MUC1 tumor-associated antigen. This patent supports the company's vector platform, focusing on creating virus-like particles (VLPs) for cancer treatment. David Dodd, CEO, highlighted encouraging results from initial studies with MVA-VLP-MUC1 and ongoing IND-enabling animal studies. Additionally, GeoVax is advancing Gedeptin®, a treatment for head and neck cancer, currently in Phase 1/2 trials. The company's immuno-oncology pipeline includes multiple vaccine candidates.

GeoVax Labs, Inc. (GOVX) announced that its Chief Scientific Officer, Mark J. Newman, will present on March 28-31, 2022, at the Vaccine Summit Boston. The presentation focuses on the design of a universal SARS-CoV-2 vaccine, GEO-CM02, which targets evolving variants. The vaccine employs a multi-antigen strategy to enhance immune responses. GeoVax is engaged in multiple clinical trials, including GEO-CM04S1 for COVID-19 and Gedeptin® for head and neck cancer, while boasting over 70 patent applications across various infectious diseases.

GeoVax Labs (Nasdaq: GOVX) has been invited to present at Maxim Group’s 2nd Annual Virtual Growth Conference from March 28-30, 2022. CEO David Dodd will provide updates on the company's immunotherapy and vaccine research, including Phase 2 clinical programs for COVID-19 and cancer. Additionally, Chief Scientific Officer Mark Newman, PhD, will engage in a fireside chat with Maxim's Jason McCarthy, PhD, on March 30, discussing cancer vaccine developments. Investors can register for the conference and request a meeting with the CEO post-event.

GeoVax Labs, Inc. (Nasdaq: GOVX) announced a partnership with CATO SMS for managing its two ongoing Phase 2 clinical trials of the COVID-19 vaccine candidate GEO-CM04S1. This synthetic vaccine aims to induce robust immune responses targeting both spike and nucleocapsid proteins. The first trial compares GEO-CM04S1's safety and immunogenicity to the Pfizer/BioNTech vaccine in immunocompromised patients, while the second trial evaluates GEO-CM04S1 as a booster for individuals previously vaccinated with Pfizer/BioNTech or Moderna vaccines. The company believes this dual-targeting approach may enhance protection against variants.

GeoVax Labs has initiated Phase 2 clinical trials for COH04S1, a COVID-19 investigational vaccine targeting both spike and nucleocapsid proteins. The vaccine displayed strong neutralizing antibody and T cell responses in Phase 1 trials, with no significant side effects. It is aimed at immunocompromised patients and as a booster for healthy adults. This dual-target approach may enhance protection against COVID-19 variants, providing vital T cell immunity, particularly for those unable to produce antibodies. GeoVax plans to expedite clinical advancement in collaboration with City of Hope.

GeoVax Labs, Inc. (Nasdaq: GOVX) reported a net loss of $18.6 million for 2021, up from $3.0 million in 2020, despite an increase in cash balances to $11.4 million. The company is advancing two Phase 2 clinical trials for its COVID-19 vaccine GEO-CM04S1, targeting immunocompromised patients, and as a booster for existing vaccines. Additionally, its Gedeptin cancer therapy is undergoing a Phase 2 trial for advanced head and neck cancer. The management emphasized a focus on accelerating clinical programs and generating significant data in 2022.